Skip to main content

Advertisement

SpringerLink
Log in

Cytokines in parvovirus b19 infection as an aid to understanding chronic fatigue syndrome

  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Human parvovirus B19 infection has been associated with various clinical manifestations of a rheumatic nature such as arthritis, fatigue, and chronic fatigue syndrome (CFS), which can persist for years after the acute phase. The authors have demonstrated recently that acute B19 infection is accompanied by raised circulating levels of IL-1β, IL-6, TNF-α, and IFN-γ and that raised circulating levels of TNF-α and IFN-γ persist and are accompanied by MCP-1 in those patients who develop CFS. A resolution of clinical symptoms and cytokine dysregulation after intravenous immunoglobulin (IVIG) therapy, which is the only specific treatment for parvovirus B19 infection, also has been reported. Although CFS may be caused by various microbial and other triggers, that triggered by B19 virus is clinically indistinguishable from idiopathic CFS and exhibits similar cytokine abnormalities and may represent an accessible model for the study of CFS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kerr JR, Bracewell J, Laing I, et al.: Chronic fatigue syndrome (CFS) and arthralgia following parvovirus B19 infection. J Rheumatol 2002, 29:595–602. This paper documents symptoms during acute and convalescent B19 infection and reports an incidence of CFS after symptomatic infection of 13% (five of 39 cases).

    PubMed  Google Scholar 

  2. Kerr JR, Barah F, Mattey DL, et al.: Serum tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol 2001, 82:3011–3019. This paper documents circulating cytokine levels in parvovirus B19-infected patients, showing that persistently detectable circulating levels of TNF-α and IFN-γ are associated with prolonged and chronic fatigue.

    PubMed  CAS  Google Scholar 

  3. Pawlikowska T, Chalder T, Hirsch SR, et al.: Population based study of fatigue and psychological distress. Br Med J 1994, 308:763–766.

    CAS  Google Scholar 

  4. Fukuda K, Straus SE, Hickie I, et al.: The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994, 121:953–959.

    PubMed  CAS  Google Scholar 

  5. Jason LA, Taylor RR, Kennedy CL: Chronic fatigue syndrome, fibromyalgia and multiple chemical sensitivities in a communitybased sample of patients with chronic fatigue syndrome-like symptoms. Psychosom Med 2000, 62:655–663.

    PubMed  CAS  Google Scholar 

  6. Aaron LA, Burke MM, Buchwald D: Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia and temporomandibular disorder. Arch Intern Med 2000, 160:221–227.

    Article  PubMed  CAS  Google Scholar 

  7. Wolfe F, Smythe HA, Yunus MB, et al.: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report for the multicenter criteria committee. Arthritis Rheum 1990, 33:160–172.

    Article  PubMed  CAS  Google Scholar 

  8. Crofford LJ, Clauw DJ: Fibromyalgia: where are we a decade after the American College of Rheumatology Classification Criteria were developed? Arthritis Rheum 2002, 46:1136–1138.

    Article  PubMed  Google Scholar 

  9. White PD, Thomas JM, Kangro HO, et al.: Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. Lancet 2001, 358:1946–1954.

    Article  PubMed  CAS  Google Scholar 

  10. Chia JK, Chia A: Diverse etiologies for chronic fatigue syndrome. Clin Infect Dis 2003, 36:671–672.

    Article  PubMed  Google Scholar 

  11. Afari N, Buchwald D: Chronic fatigue syndrome: a review. Am J Psychiatry 2003, 160:221–236.

    Article  PubMed  Google Scholar 

  12. Komaroff AL, Buchwald DS: Chronic fatigue syndrome: an update. Annu Rev Med 1998, 49:1–13.

    Article  PubMed  CAS  Google Scholar 

  13. Chao CC, Janoff EN, Hu SX, et al.: Altered cytokine release in PBMC cultures from patients with the chronic fatigue syndrome. Cytokine 1991, 3:292–298.

    Article  PubMed  CAS  Google Scholar 

  14. MacDonald KL, Osterholm MT, LeDell KH, et al.: A case control study to assess possible triggers and cofactors in chronic fatigue syndrome. Am J Med 1996, 100:548–554.

    Article  PubMed  CAS  Google Scholar 

  15. Rook GA, Zumla A: Gulf war syndrome: Is it due to a systemic shift in cytokine balance to a Th2 profile? Lancet 1997, 349:1831–1833.

    Article  PubMed  CAS  Google Scholar 

  16. Patarca R: Cytokines and chronic fatigue syndrome. Ann NY Acad Sci 2001, 933:185–200.

    Article  PubMed  CAS  Google Scholar 

  17. Penttila IA, Harris RJ, Storm P, et al.: Cytokine dysregulation in the post-Q-fever fatigue syndrome. Q J Med 1998, 91:549–560.

    CAS  Google Scholar 

  18. Maes M, Scharpe S, Meltzer HY, et al.: IL-6, acute phase proteins and function of the HPA axis in severe depression. Psychiat Res 1992, 49:11–27.

    Article  Google Scholar 

  19. Maes M: Evidence for immune response in major depression. Prog Neuropsychopharmacol Biol Psychiat 1995, 19:11–38.

    Article  CAS  Google Scholar 

  20. Ur E, White PD, Grossman A: Hypothesis: cytokines may be activated to cause depressive illness and CFS. Eur Arch Psychiat Clin Neurosci 1992, 241:317–322.

    Article  CAS  Google Scholar 

  21. Zalcman S, Green-Johnson JM, Murray L, et al.: Cytokinespecific central monoamine alterations induced by interleukin 1, 2 and 6. Brain Res 1994, 643:40–49.

    Article  PubMed  CAS  Google Scholar 

  22. Modolell M, Corraliza IM, Link F, et al.: Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by Th1 and Th2 cytokines. Eur J Immunol 1995, 25:1101–1104.

    Article  PubMed  CAS  Google Scholar 

  23. Bennett AL, Chao CC, Hu S, et al.: Elevation of bioactive transforming growth factor-beta in serum of patients with chronic fatigue syndrome. J Clin Immunol 1997, 17:160–166.

    Article  PubMed  CAS  Google Scholar 

  24. Peterson PK, Sirr SA, Grammith FC, et al.: Effects of mild exercise on cytokines and cerebral blood flow in chronic fatigue syndrome patients. Clin Diagn Lab Immunol 1994, 1:222–226.

    PubMed  CAS  Google Scholar 

  25. Rasmussen AK, Nielsen H, Andersen V, et al.: Chronic fatigue syndrome: a controlled cross-sectional study. J Rheumatol 1994, 21:1527–1531.

    PubMed  CAS  Google Scholar 

  26. Patarca R, Klimas NG, Lugtendorf S, et al.: Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis 1994, 18(suppl 1):S147-S153.

    PubMed  Google Scholar 

  27. Moss RB, Mercandetti A, Vojdani A: TNF-α and chronic fatigue syndrome. J Clin Immunol 1999, 19:314–316.

    Article  PubMed  CAS  Google Scholar 

  28. Curti BD, Smith JW 2nd: Interleukin-1 in the treatment of cancer. Pharmacol Ther 1995, 65:291–302.

    Article  PubMed  CAS  Google Scholar 

  29. Dillman RO: The clinical experience with interleukin-2 in cancer therapy. Cancer Biother 1994, 3:183–209.

    Google Scholar 

  30. Wadler S: The role of interferons in the treatment of solid tumors. Cancer 1992, 15:949–958.

    Google Scholar 

  31. Mani S, Poo WJ: Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma. Am J Clin Oncol 1996, 19:149–153.

    Article  PubMed  CAS  Google Scholar 

  32. Choy EH, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001, 344:907–916.

    Article  PubMed  CAS  Google Scholar 

  33. Klimas NG, Fletcher MA: Alteration of type 1/type 2 cytokine pattern following adoptive immunotherapy of patients with chronic fatigue syndrome (CFS) using autologous ex vivo expanded lymph node cells [Abstract]. Presented at the II International Conference on CFS. Brussels: 1999.

  34. Wallace DJ, Linker-Israeli M, Hallegua D, et al.: Cytokines play an etiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology 2001, 40:743–749.

    Article  PubMed  CAS  Google Scholar 

  35. Gur A, Karakoc M, Nas K, et al.: Cytokines and depression in cases with fibromyalgia. J Rheumatol 2002, 29:358–361.

    PubMed  Google Scholar 

  36. Pache M, Ochs J, Genth E, et al.: Increased plasma endothelin-1 levels in fibromyalgia syndrome. Rheumatology 2003, 42:493–494.

    Article  PubMed  CAS  Google Scholar 

  37. Nairn C, Galbraith DN, Clements GB: Comparison of coxsackie B neutralisation and enteroviral PCR in chronic fatigue patients. J Med Virol 1995, 46:310–313.

    Article  PubMed  CAS  Google Scholar 

  38. Ayres JG, Flint N, Smith EG, et al.: Post-infection fatigue syndrome following Q-fever. Q J Med 1998, 91:105–123.

    CAS  Google Scholar 

  39. Hotopf M, Noah N, Wessely S: Chronic fatigue and minor psychiatric morbidity following viral meningitis. J Neurol Neurosurg Psych 1996, 60:504–509.

    Article  CAS  Google Scholar 

  40. Berelowitz GJ, Burgess AP, Thanabalasingham T, et al.: Posthepatitis syndrome revisited. J Viral Hepat 1995, 2:133–138.

    PubMed  CAS  Google Scholar 

  41. National Task Force on CFS/ME: Second Report. Report on NHS Services for people with Chronic Fatigue Syndrome / Myalgic Encephalomyelitis. Westcare Bristol: UK; 1994.

    Google Scholar 

  42. Cossart YE, Field AM, Cant B, Widdows D: Parvovirus-like particles in human sera. Lancet 1975, 1:72–73.

    Article  PubMed  CAS  Google Scholar 

  43. Brown KE, Anderson SM, Young NS: Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993, 262:114–117.

    Article  PubMed  CAS  Google Scholar 

  44. Cooling LL, Koerner TA, Naides SJ: Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. J Infect Dis 1995, 172:1198–1205.

    PubMed  CAS  Google Scholar 

  45. Kerr JR: Pathogenesis of human parvovirus B19 in rheumatic disease. Ann Rheum Dis 2000, 59:903–908.

    Article  Google Scholar 

  46. Anderson MJ, Higgins PG, Davis LR, et al.: Experimental parvoviral infection in humans. J Infect Dis 1985;152:257–265.

    PubMed  CAS  Google Scholar 

  47. Takeda S, Takaeda C, Takazakura E, Haratake J: Renal involvement induced by human parvovirus B19 infection. Nephron 2001, 89:280–285.

    Article  PubMed  CAS  Google Scholar 

  48. Kasuga A, Harada R, Saruta T: Insulin-dependent diabetes mellitus associated with parvovirus B19 infection. Ann Intern Med 1996, 125:700–701.

    PubMed  CAS  Google Scholar 

  49. Lunardi C, Tiso M, Borgato L, et al.: Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol 1998, 28:936–948.

    Article  PubMed  CAS  Google Scholar 

  50. Trapani S, Ermini M, Falcini F: Human parvovirus B19 infection: its relationship with systemic lupus erythematosus. Semin Arthritis Rheum 1999, 28:319–325.

    Article  PubMed  CAS  Google Scholar 

  51. Narvaez-Garcia FJ, Domingo-Domenech E, Castro-Bohorquez FJ, et al.: Lupus-like presentation of parvovirus B19 infection. Am J Med 2001, 111:573–575.

    Article  PubMed  CAS  Google Scholar 

  52. Kurtzman GJ, Frickhofen N, Kimball, et al.: Pure red cell aplasia of 10 years duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989, 321:519–523.

    Article  PubMed  CAS  Google Scholar 

  53. Schwarz TF, Roggendorf M, Hottentrager B, et al.: Immunoglobulins in the prophylaxis of parvovirus B19 infection. J Infect Dis 1990, 162:1214.

    PubMed  CAS  Google Scholar 

  54. Von Poblotzki A, Gerdes C, Reischl U, et al.: Lymphoproliferative responses after infection with human parvovirus B19. J Virol 1996, 70:7327–7330.

    Google Scholar 

  55. Franssila R, Soderlung M, Brown SB, et al.: IgG response to parvovirus B19 infection. Clin Diagn Virol 1996, 6:41–49.

    Article  PubMed  CAS  Google Scholar 

  56. Wagner AD, Goronzy JJ, Matteson EL, Weyand CM: Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection. Mayo Clin Proc 1995, 70:261–265.

    PubMed  CAS  Google Scholar 

  57. Goodbourn S, Didcock L, Randall RE: Interferons: cell signaling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 2000, 81:2341–2364.

    PubMed  CAS  Google Scholar 

  58. Hunter CA, Reiner SL: Cytokines and T cells in host defense. Curr Opin Immunol 2000, 12:413–418.

    Article  PubMed  CAS  Google Scholar 

  59. Hillingso JG, Jensen IP, Tom-Petersen L: Parvovirus B19 as a cause of acute liver symptoms in adults. Ugeskr Laeger 1998, 160:6355–6356.

    PubMed  CAS  Google Scholar 

  60. Adlakha A, Schultz HJ: Rash, arthropathy and fatigue in a young woman. Hosp Pract 1994, 29:149–152.

    CAS  Google Scholar 

  61. Keonigbauer UF, Eastlund T, Day JW: Clinical illness due to parvovirus B19 infection after infusion of solvent/detergenttreated pooled plasma. Transfusion 2000, 40:1203–1206.

    Article  Google Scholar 

  62. Hayakawa H, Tara M, Niina K, Osame M: A clinical study of adult human parvovirus B19 infection. Intern Med 2002, 41:295–299.

    PubMed  Google Scholar 

  63. Jobanputra P, Davidson F, Graham S, et al.: High frequency of parvovirus B19 in patients tested for rheumatoid factor. BMJ 1995, 311:1542.

    PubMed  CAS  Google Scholar 

  64. Kerr JR, Coyle PV, DeLeys RJ, Patterson CC: Follow-up study of clinical and immunological findings in patients presenting with acute parvovirus B19 infection. J Med Virol 1996, 48:68–75.

    Article  PubMed  CAS  Google Scholar 

  65. Jacobsen SK, Daly JS, Thorne GM, McIntosh K: Chronic parvovirus B19 infection resulting in chronic fatigue syndrome: case history and review. Clin Infect Dis 1997, 24:1048–1051.

    Google Scholar 

  66. Leventhal LJ, Naides SJ, Freundlich B: Fibromyalgia and parvovirus infection. Arthritis Rheum 1991, 34:1319–1324.

    Article  PubMed  CAS  Google Scholar 

  67. Ballou WR, Reed JL, Noble W, et al.: Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003, 187:675–678.

    Article  PubMed  CAS  Google Scholar 

  68. Koelle DM, Barcy S, Huang ML, et al.: Markers of viral infection in monozygotic twins discordant for chronic fatigue syndrome. Clin Infect Dis 2002, 35:518–525.

    Article  PubMed  Google Scholar 

  69. Ilaria RL Jr, Komaroff AL, Fagioli LR, et al.: Absence of parvovirus B19 infection in chronic fatigue syndrome. Arthritis Rheum 1995, 38:638–641.

    Article  PubMed  Google Scholar 

  70. Kerr JR, Mattey DL, Thomson W, et al.: Association of symptomatic acute human parvovirus B19 infection with human leukocyte antigen class I and II alleles. J Infect Dis 2002, 186:447–452.

    Article  PubMed  CAS  Google Scholar 

  71. Kerr JR, Cunniffe VS, Kelleher P, et al.: Successful intravenous immunoglobulin (IVIG) therapy in three cases of parvovirus B19-associated chronic fatigue syndrome (CFS). Clin Infect Dis 2003, 36:e100-e106. Description of the symptoms and B19 markers in three cases of parvovirus B19-associated CFS along with documentation of cytokine dysregulation. These patients were treated with intravenous immunoglobulin, the only specific treatment for parvovirus B19 infection, which was followed by complete resolution of clinical symptoms and normalization of cytokine levels.

    Article  PubMed  CAS  Google Scholar 

  72. Fehniger TA, Cooper MA, Caligiuri MA: Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002, 13:169–183.

    Article  PubMed  CAS  Google Scholar 

  73. Spellberg B, Edwards JE Jr: Type 1/type 2 immunity in infectious diseases. Clin Infect Dis 2001, 32:76–102.

    Article  PubMed  CAS  Google Scholar 

  74. Jordan JA, Huff D, DeLoia JA: Placental cellular immune response in women infected with human parvovirus B19 during pregnancy. Clin Diagn Lab Immunol 2001, 8:288–292.

    Article  PubMed  CAS  Google Scholar 

  75. Watanabe M, Shimamoto Y, Yamaguchi M, et al.: Viral-associated hemophagocytosis and elevated TNF-α with parvovirus B19-related pancytopenia in patients with hereditary spherocytosis. Clin Lab Hematol 1994, 16:179–182.

    Article  CAS  Google Scholar 

  76. Nigro G, Bastianon V, Colloridi V, et al.: Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Infect Dis 2000, 31:65–69. This paper reports three cases of acute lymphocytic myocarditis associated with acute B19 infection and raised circulating levels of IL-6, IL-8, TNF-α, and IFN-γ.

    Article  PubMed  CAS  Google Scholar 

  77. Corcoran A, Doyle S, Waldron D, et al.: Impaired gamma interferon responses against parvovirus b19 by recently infected children. J Virol 2000, 74:9903–9910. This study documents impaired IFN-γ responses against B19 antigen in children compared with adults, suggesting a possible reason for the reduced incidence of B19-associated symptoms in childhood.

    Article  PubMed  CAS  Google Scholar 

  78. Otto CM, Drobatz KJ, Soter C: Endotoxemia and tumor necrosis factor activity in dogs with naturally occurring parvoviral enteritis. J Vet Intern Med 1997, 11:65–70.

    Article  PubMed  CAS  Google Scholar 

  79. Chung YH, Jun HS, Kang Y, et al.: Role of macrophages and macrophage-derived cytokines in the pathogenesis of Kilham rat virus-induced autoimmune diabetes: diabetes-resistant biobreeding rats. J Immunol 1997, 159:466–471.

    PubMed  CAS  Google Scholar 

  80. Moffatt S, Tanaka N, Tada K, et al.: A cytotoxic non-structural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol 1996, 70:8485–8491.

    PubMed  CAS  Google Scholar 

  81. Pahl HL: Activators and target genes of Rel/NF-KB transcription factors. Oncogene 1999, 18:6853–6856.

    Article  PubMed  CAS  Google Scholar 

  82. Kerr JR, Cunniffe VS, Mattey DL, et al.: Circulating cytokines and chemokines during symptomatic acute and convalescent parvovirus B19 infection. J Med Virol 2003 (submitted). A description of extended cytokine / chemokine profiles in acute and convalescent parvovirus B19 infection, documenting the relevance of IL-4, IL-8, TNF-α, IFN-γ, MCP-1, GM-CSF, TGF-β1, endothelin-1, and neopterin.

  83. Magro CM, Crowson AN, Dawood M, Nuovo GJ: Parvoviral infection of endothelial cells and its possible role in vasculitis and autoimmune diseases. J Rheumatol 2002, 29:1227–1235.

    PubMed  Google Scholar 

  84. Schennach H, Lanthaler AJ, Mayersbach P, et al.: Human parvovirus B19 detection in asymptomatic blood donors: association with increased neopterin concentrations. J Infect Dis 2002, 186:1494–1497.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology, Royal Brompton Hospital, National Heart & Lung Institute, Imperial College London, Sydney Street, SW3 6NP, London, UK

    Jonathan R. Kerr MD

  2. CFS Research Foundation, Salisbury, Wiltshire

    David A. J. Tyrrell MD

Authors
  1. Jonathan R. Kerr MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. J. Tyrrell MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kerr, J.R., Tyrrell, D.A.J. Cytokines in parvovirus b19 infection as an aid to understanding chronic fatigue syndrome. Current Science Inc 7, 333–341 (2003). https://doi.org/10.1007/s11916-003-0031-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11916-003-0031-3

Keywords

Search

Navigation